Status:

UNKNOWN

A Novel Endoloop Pre-test to Treat Gastroesophageal Reflux

Lead Sponsor:

Affiliated Hospital to Academy of Military Medical Sciences

Collaborating Sponsors:

Beijing 302 Hospital

Beijing Hospital

Conditions:

GERD

Reflux Esophagitis

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

The purpose of this study was to evaluate the safety and efficacy of endoscopic endoloop pre-test for gastroesophageal reflux before anti-reflux surgery or endoscopic treatment. In the study, the inve...

Detailed Description

Gastroesophageal reflux disease (GERD) is a neuromuscular disorder with abnormal reflux of gastric contents into the esophagus.The most common symptoms are heartburn, dysphagia, and regurgitation.Due ...

Eligibility Criteria

Inclusion

  • Patients with typical symptoms of GERD with symptomatic response to PPI therapy for ≥ 3 months
  • Patients considered for non-medical therapy, i.e. unwillingness to take life-long medication in medically-responding disease, suffering from medication side-effects or medically-intractable disease
  • Pathological esophageal acid exposure after discontinuation of medical therapy, proven by ambulatory 24-hour pH-monitoring with \> 5% of time a pH \< 4 and a symptom-association probability \> 95%
  • written informed consent

Exclusion

  • 24 hr acid exposure study showing abnormal esophageal acid exposure \<4%
  • DeMeester Score \<14.7
  • hiatal hernia (\> 3 cm in length)
  • history of antireflux or esophageal/gastric surgery
  • severe psychiatric disease
  • Barrett's esophagus with dysplasia
  • esophageal stenosis/malignancy
  • pregnancy or lactation
  • history of low therapeutic compliance
  • other severe comorbidity (including cardiopulmonary disease, portal hypertension, collagen diseases, morbid obesity, coagulation disorder)
  • use of anticoagulant or immunosuppressive drugs

Key Trial Info

Start Date :

February 10 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2022

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT05192538

Start Date

February 10 2022

End Date

May 1 2022

Last Update

March 16 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Fifth Medical Center of Chinese PLA General Hospital

Beijing, Beijing Municipality, China, 100071